At first, everyone just assumed there would be an advisory committee review.
As a first-in-class cannabinoid-1 receptor agonist—essentially an "anti-marijuana" effect in a pill—with a potential for broad off-label use, Sanofi-Aventis ...
Debunking Acomplia
Sanofi's Acomplia fit all the criteria for an advisory committee review. But despite some safety concerns, FDA had good reasons not to hold one.